Background. Multiprogrammable antiarrhythmia devices can treat monomorphic ventricular tachycardia (VT) with autodecremental overdrive pacing and/or with low-energy cardioversion. These two methods provide the opportunity to decrease patient discomfort typically experienced with high-energy pulses.
therapy is required to facilitate optimal device programming.
A simple, all-encompassing comparative study to answer whether ATP is reproducibly preferable to LEC in a prospective randomized way is not possible. Too many pacing options are available in tiered therapy antiarrhythmia devices to allow a comparison of all pacing possibilities. Thus, because of the range of ATP options available and the clinical limitations of repetitive inductions of VT, the question was examined for only one particular form of ATP, overdrive decremental antitachycardia pacing, previously demonstrated to be effective. 5, 6 Methods After giving informed consent, 24 patients with a tiered therapy antiarrhythmia device (Medtronic 7217B PCD) were enrolled in a prospective randomized, repeat-crossover comparison of ATP to LEC for the treatment of monomorphic VT.
Entry into the study required that the same QRS morphology monomorphic VT be inducible four times with programmed electrical stimulation performed via a telemetry link to the implanted device. This requirement allowed each therapy, ATP and LEC, to be examined twice, thereby testing reproducibility of outcome. The group of 24 patients that satisfied the entry criteria derived from a population of 110 patients. The other 86 patients either did not have inducible monomorphic VT or did not have the same VT morphology induced four times to allow for repeat crossover evaluation of the two therapies.
Constancy of VT morphology for each of the four VT episodes was ensured by examining the QRS configuration in ECG leads I, II, III, and V, during each episode of VT. Moreover, it was required that cycle length during a VT episode as well as between VT episodes could not waver by >10 msec as a criterion for study entry. Patients with monomorphic VT with cycle lengths <240 msec were not included in this study because of the concern that such patients generally require prompt and definitive therapy with high-energy cardioversion.
The entire study for each patient was conducted under general anesthesia, for two reasons. First, clinical evaluation of defibrillation efficacy was performed concomitantly with the study herein described. The pain and fear associated with high-energy shocks during ventricular defibrillation testing would not be tolerable. Second, during VT testing, ATP or LEC could accelerate VT into ventricular fibrillation (VF), which would in turn trigger rapid delivery of a defibrillation pulse by the device before loss of consciousness. The additional discomfort and fear associated with acceleration episodes also motivated us to perform the procedure under general anesthesia, thereby ensuring patient comfort throughout the study.
The type of ATP used in this study was overdrive autodecremental pacing, previously demonstrated to be effective at pace termination of monomorphic VT.5'6 We selected a specific set of pacing parameters from a large pool of alternatives to eliminate arbitrary variations in pacing methods from patient to patient. The specific parameters chosen were selected as most likely to be beneficial according to previous publications and from clinical experience.5 '6 Seven stimuli were used for the first ATP intervention. This initial attempt to pace terminate VT was delivered such that the first stimulus always occurred at 97% of the VT cycle length. Each successive stimulus was decremented by 10 msec per pulse to the minimum pacing cycle length of 200 msec. This minimum pacing cycle length was consistently programmed to 200 msec throughout the study. A total of four ATP attempts were allowed by the device. Stimulus number incremented by one with each ATP iteration. Thus, for the second ATP sequence, eight stimuli were delivered; for the third, nine stimuli; and for the fourth, ten stimuli.
LEC was defined as a stored energy cardioversion pulse of .2.0 J. The pulsing method used to deliver the LEC shock matched the pulsing method that provided the most efficient defibrillation therapy. As with ATP, four LEC attempts were allowed to terminate the ing by the overseeing electrophysiologist. LEC always began with a synchronized 0.2-J cardioversion pulse. Subsequent synchronized LEC pulses 2, 3, and 4 were 0.4-, 1.0-, and 2.0-J pulses, respectively. Because this study was intended to simulate device function in an unsupervised setting, ATP and LEC therapies were delivered by use of the device's own VT detection algorithm, which was activated immediately after VT induction. The tachycardia detection algorithm was programmed to allow VT detection for any tachyarrhythmia with a cycle length >240 msec that persisted for 16 consecutive VT intervals before delivery of the first VT therapy. Should the first VT therapy fail, each subsequent attempt required that 16 consecutive intervals once again satisfy the detection algorithm. Additional features to the detection scheme, like stability functions and onset functions,5'14"5 were not included in the detection algorithm for this study.
VT therapy was deemed successful for either therapy only if the VT was terminated with the method under study for both occasions for which the therapy was examined. VT therapy was defined as accelerating VT if it changed VT into a faster VT (30 msec shorter cycle length) or if it changed VT into VF during one or both of the two occasions that that particular mode of therapy was being examined. VT therapy was deemed ineffective if either of the two episodes was not terminated by the method being examined. Examples of VT therapy success and failure are shown in Figure 1 . Paired Student's t tests were used to compare efficacy and risk of each form of therapy. Patient acceptance of each therapy could not be analyzed. The use of general anesthesia prevented an assessment of patient comfort during therapy, which, in the case of LEC, would have been especially helpful.
Results
Of 110 patients with tiered therapy antiarrhythmia devices available for study, only 24 satisfied the criteria of entry: four identical episodes of inducible monomorphic VT. VT was inducible in 25 patients, but the VT could not be reproducibly initiated for study. An additional 61 patients were survivors of VF with no inducible monomorphic VT; these individuals were either noninducible altogether, had inducible VF, or had inducible nonsustained VT. Thus, reproducible evaluation of therapy for monomorphic VT with this protocol was possible in only a minority of our patients receiving a tiered therapy device, 24 of 110 (22%). The clinical data for these 24 patients are summarized in Table 1 .
The mean age of the 24 patients with reproducibly inducible VT was 60±13 years (range, 29-79 years). Twenty-two (92%) were men. The underlying structural heart disease was coronary artery disease in 13, cardiomyopathy in three, coronary artery disease and cardiomyopathy in five, right ventricular dysplasia in two, and congenital heart disease in one. The mean left ventricular ejection fraction was 0.34+0.14 (range, 0.16-0.70). The index arrhythmia leading to device implantation was VT in 12, VF in three, and both VT and VF in nine. Fifteen patients had a transvenous/subcutaneous patch nonthoracotomy lead system, and nine had an epicardial lead system. The mean VT cycle length in these 24 episode of VT before intervention into device function-patients was 306-t-42 msec (range, 250-450 msec). The results of ATP success and failure are delineated in Tables 2-6. In the 24 patients in whom four identical episodes of monomorphic VT were inducible, both ramp ATP and LEC were reproducibly successful in 10 of 24 patients (42%). Ramp ATP alone was reproducibly successful in five of 24 patients (21%), and LEC alone was reproducibly successful in eight of 24 patients (33%) (p=0.52). Ramp ATP and/or LEC was reproducibly successful in 23 of 24 patients (96%). The mean successful energy for LEC was 0.46±0.39 J.
Ramp ATP accelerated VT in four of 24 patients (17%) (Figure 1 , panel E). LEC accelerated VT in five of 24 patients (21%) (Figure 1 , panel F). Both ramp ATP and LEC accelerated VT in one of 24 patients (4%). Ramp ATP and/or LEC accelerated VT in eight of 24 patients (33%). Neither ATP nor LEC left the VT unaltered, for better or for worse, for each of the two episodes of VT in our population.
No clinical factors were statistically associated with the success or failure of ATP compared with LEC, including the patient's age, the presence or absence of coronary artery disease, left ventricular ejection fraction, device lead system, VT cycle length, or VT QRS morphology.
The manner by which monomorphic VT terminated after ATP or LEC did not differ. ATP was not more likely to terminate VT cleanly compared with LEC (p=0.32). (A clean VT termination, defined as a type I break, was described as the first event after therapy being a sinus beat or a ventricular-inhibited paced beat rather than a repetitive ventricular response [ Figure 1 , panels A and B].) In the case of ATP, 16 of 24 patients (67%) experienced at least one repetitive ventricular response after ATP before restoration of sinus rhythm (Figure 1 , panels C and D). The mean number of repetitive ventricular responses before VT termination after ATP was 6±5 (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . In the case of LEC, 12 of 24 patients (50%) experienced some repetitive ventricular response before restoration of sinus rhythm. The mean number of repetitive ventricular responses before VT termination after LEC was 5±4 (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . These repetitive ventricular responses were always polymorphic in nature and did not correspond to the QRS morphology of the VT under treatment. Nonsustained polymorphic VT after therapy was defined as a type II break. 
Discussion

History ofAntitachycardia Pacing and Low-Energy Cardioversion
The value of ATP as a painless means of terminating monomorphic VT was recognized in 1970 by Wellens.8 It was not until the late 1970s, however, that ATP of VT began to be used in permanent pacemakers. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] However, as soon became apparent, treatment of VT by stand-alone antitachycardia pacemakers without the ca- pacity to provide back-up defibrillation carried too high a risk. The potential of accelerating VT to VF did not justify the widespread use of antitachycardia pacemakers, and they ultimately fell out of favor.'6-'9 '22-27'3435 Rudimentary efforts also were made to use LEC. The initial use of LEC was in intensive care units and in the electrophysiology laboratory.10-'3 Subsequently, an implantable device capable of LEC was developed as a possible alternative to antitachycardia pacemakers with the expectation that it would minimize the discomfort associated with high-energy shocks yet not carry the risk of VT acceleration shown with ATP.1 However, the implantable low-energy cardioverter also proved capable of accelerating VT to VF.9 Without back-up highenergy defibrillation, the unit could not be used safely and therefore fell into disuse.
The difficulties with early device attempts to treat monomorphic VT have not removed the therapeutic appeal of either ATP or LEC. Both forms of device therapy, especially ATP, remain preferable to highenergy cardioversion from a comfort perspective. Moreover, ATP and LEC provide an opportunity to minimize antiarrhythmic drug usage.5,36 Given the controversy over antiarrhythmic drug efficacy in treating VT,37-42 the use of device therapy alone has substantial appeal as long as ATP and LEC are viable alternatives. Thus, with the myriad number of ATP and LEC therapeutic options present in tiered therapy antiarrhythmia devices, the task is one of choosing the most effective and least risky way to terminate monomorphic VT.
Relative Efficacy ofATP and LEC
The results of this study show that both ramp ATP, as defined in this protocol, and LEC have similar efficacy rates. Reproducible termination of monomorphic VT was 63% and 75% for ATP and LEC, respectively (p=0.53). Similarly, both ATP and LEC had a modest and near equal risk of accelerating VT (16% and 21%; p=0.88). This stated, it was also clear that some individuals responded better than others to one form of therapy over the other. Moreover, there was no way to satisfactorily predict who would and who would not accelerate with therapy.
The VT termination and acceleration results from this study suggest that it is unwise to empirically program an ATP or LEC method without first subjecting the patient to an examination of ATP/LEC efficacy and safety. It should be recognized, however, that the value of ATP/LEC testing may be restricted to those with reproducibly inducible monomorphic VT. Trying to detect a beneficial or proarrhythmic response to ATP or LEC in those without reproducibly inducible monomorphic VT may not be possible simply because one particular VT morphology may not be as easily elicited as desired, or, as is the case in many cardiac arrest survivors, the patient is noninducible altogether.4344 These difficulties in evaluating ATP/LEC device efficacy and safety on a trial-and-error basis in those without reproducibly inducible monomorphic VT argue that an empirical approach to ATP or LEC programming based on clinical experience may be as reasonable as any other approach for this subpopulation of patients.
Mechanisms ofATPILEC Failure and Success
In our study, several reasons are postulated for why 29% of VT episodes could not be terminated by ATP and 15% were not terminated by LEC. One reason is simply that ATP and LEC inefficacy reflect our inability to examine all conceivable pacing and cardioversion modalities for each patient. If ATP or LEC parameters were varied from those used in this protocol, either therapy, or both, could prove more effective. Other causes of ATP/LEC failure may be rooted in the supervening effect of anesthetics that might have influenced the ability to interrupt VT. One intriguing outcome of the study is the demonstration that in five patients (21%), one of the two ATP therapies or one of the two LEC therapies would terminate VT, whereas the other would accelerate it. This suggests that the physician may need to accept a degree of unpredictability in any programming option selected. Ultimately, the physician's ability to control outcome for any therapeutic alternative must be recognized as limited. VT termination by any therapy will be probabilistic and subject to influences beyond our ken.
Another unexpected finding was that VT termination by either ATP or LEC was not dependent on the lead system used. It was anticipated that ATP would prove more effective with endocardial lead systems because they manifest less exit block and that LEC would prove more effective with epicardial lead systems because they produce a more efficient electric field distribution across the ventricles. Neither lead system significantly influenced outcome. It must be recognized, however, that the number of patients in each category was small and that larger population numbers might have shown a difference. Moreover, the efficacy of ATP may be dictated more by location of the stimulus with respect to the VT site of origin than by lead system. Similarly, the efficacy of LEC may depend more on timing of shock delivery with respect to VT origin than on electric field distribution.
In this study, it was also surprising to witness how infrequently VT of the same morphology could be induced. Of 110 patients with tiered therapy devices in our study, only 24 (22%) could be examined in a strict reproducibility protocol. Even in these 24 patients, induction of four episodes of VT of the same morphology required considerable persistence and time. Second and third VT morphologies were often encountered in this group, which increased the number of inductions required before the four episodes of VT needed for study were obtained. Thus, the practical message from this study may be that detailed testing of any VT therapy will not be possible in the majority of cardiac arrest or sustained VT survivors who receive such devices.
This study also revealed some information about mechanisms of VT termination. An "unclean" termination, in which monomorphic VT transiently degenerated to polymorphic VT before sinus rhythm was restored, called a type II break, was rather common, observed in 67% of patients whose VT was ultimately terminated by ATP and in 50% of patients whose VT was terminated by LEC (Figure 1 , panels C and D). One might therefore expect type II breaks to occur commonly. The implication of this finding is relevant to VT redetection algorithms. A certain degree of instability in the rhythm after VT therapy should be anticipated in programming device redetection algorithms before sequencing into another ATP or LEC maneuver. Limitations There are several limitations to this study. One limitation is the intentional selection of 240 msec as the minimum VT cycle length value for which ATP or LEC could be used. This limitation was driven by the clinical with extremely rapid VT and by the need to ensure safe detection of VF should it occur. Attempting ATP or LEC into short cycle length monomorphic VT, <240 msec, would require setting the VF detection interval to <240 msec. Such a short cycle length detection criterion for VF could potentially compromise VF detection because of the variability in VF not only from patient to patient but within each patient from episode to episode.45 Therefore, it was deemed impractical to examine the role of ATP or LEC for such fast arrhythmias.
Restricting ATP and LEC to only four attempts at terminating VT is also a limitation. More attempts to terminate the VT might have yielded better results. However, the decision to use only four pacing attempts was based on the desire to limit VT duration to 1 minute before delivery of definitive high-energy cardioversion. Prolonged episodes of VT, no matter how well tolerated initially, usually lead to hypotension and ischemia. Consequently, excessive attempts to terminate the rhythm painlessly with ATP have risks that seemed, in our experience, too high to justify.
Another limitation to this study is the inability to examine all of the numerous alternative ATP and LEC techniques available. The sheer number of alternatives makes it difficult to draw broad conclusions about ATP or LEC efficacy or safety. Consequently, any conclusions regarding efficacy and safety will be limited to the therapeutic modalities chosen in this study.
This study also did not address the issue of patient acceptance. The fact that the patients were examined under general anesthesia did not allow us to assess patient tolerance of therapy. In practice, we have noticed that patients can discern a difference between 1-J and 30-J pulses and that they prefer the lower-energy shocks. Nevertheless, patients usually are frightened after LEC, whereas they rarely complain about ATP. It has been our experience, and that of others,1,9 that patients are likely to be made uncomfortable with LEC unless pulses are <0.5 J. Thus, despite the relative equivalency of ATP to LEC in terminating monomorphic VT, ATP remains preferable as an initial therapy unless LEC is shown to be safer or more effective.
A final difficulty will be in comparing the results of this study with those of earlier work. Much of our understanding of ATP and LEC is derived from studies performed in the electrophysiology laboratory. In this setting, physician overview and control of ATP or LEC is a substantially different therapy from what an implantable device might deliver without human interference. This makes it difficult to draw parallels between the electrophysiology laboratory therapy of previous studies and that of today's automatic antiarrhythmia device therapy.
Conclusions
In conclusion, this study has demonstrated that it is difficult to reproducibly induce and evaluate any form of therapy for monomorphic VT. It is possible in only a minority of patients. In those patients in whom ramp ATP or LEC could be reproducibly examined, the incidence of success or failure in terminating monomorphic VT, as well as the risk of accelerating VT, was similar for either form of therapy. Although there is some overlap in outcome, certain individuals will respond more favorably to one form of therapy over the imperative for prompt, definitive therapy in patients Bardy et al Antitachycardia Pacing 1895 other. Thus, programming therapies in those individuals with reproducibly inducible monomorphic VT should be guided by empirical testing. However, in those patients without such compliant forms of VT, programming tiered therapy device interventions remains more of an art form than a science.
